Bristol-Myers Squib

1 stories about Bristol-Myers Squib
ענת כהן-דייג מנכ"לית קומפיוג'ן

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb